维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

劳动节休市 04-30 16:08:13

80.000

-0.850

-1.05%

最高81.950	最低78.400	成交量47.84万
今开80.050	昨收80.850	日振幅4.39%
总市值159.20亿	流通市值122.40亿	总股本1.99亿
成交额3,818万	换手率0.31%	流通股本1.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":80,"timestamp":1777536493009,"preClose":80.85,"halted":0,"volume":478395,"delay":0,"changeRate":-0.010513296227581872,"floatShares":153000000,"shares":199000000,"eps":-1.3872897591541022,"marketStatus":"劳动节休市","change":-0.85,"latestTime":"04-30 16:08:13","open":80.05,"high":81.95,"low":78.4,"amount":38180497,"amplitude":0.043908,"askPrice":80.1,"askSize":800,"bidPrice":79.95,"bidSize":1400,"shortable":3,"etf":0,"ttmEps":-1.349454583904445,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":7,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":80.85,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":0.7637407725676446,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887","defaultTab":"news","newsList":[{"id":"2630635700","title":"港股异动 | 维立志博-B(09887)午后涨超4% 核心产品LBL-024上市在即 展现重磅单品潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2630635700","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630635700?lang=zh_cn&edition=full","pubTime":"2026-04-27 14:52","pubTimestamp":1777272738,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B午后涨超4%，截至发稿，涨2.28%，报85.3港元，成交额3735.49万港元。消息面上，维立志博近日宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信联合用药一线治疗局部晚期或转移性胃或胃食管结合部腺癌的Ⅱ期临床研究顺利完成首例患者入组。兴业证券则表示，LBL-024 上市在即展现重磅单品潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK4585","IPOS","VXUS","HK0000252152.HKD","09887","BK4588","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113586825","title":"维立志博-B（09887）2025年收入达1.77亿元 研发与管线布局加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1113586825","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113586825?lang=zh_cn&edition=full","pubTime":"2026-04-24 21:55","pubTimestamp":1777038930,"startTime":"0","endTime":"0","summary":"维立志博-B在2025年度实现收入人民币1.77亿元，较此前尚无收入的阶段取得重大突破。报告期内，公司年内亏损收窄至人民币2.11亿元，较2024年的3.01亿元下降约29.8%。管理层将收入增长主要归因于与Dianthus Therapeutics就LBL-047订立的许可协议及后续里程碑款项，而亏损收窄则得益于收入贡献提升及股权回购义务终止后产生的公允价值损失不再确认等因素。同期行政开支约为人民币0.83亿元，较上年度略有减少，主要系部分股份支付费用在前期集中确认。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B（09887）2025年收入达1.77亿元 研发与管线布局加速推进","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179759333","title":"维立志博-B授予董事股份购回授权，规模达已发行H股一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1179759333","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179759333?lang=zh_cn&edition=full","pubTime":"2026-04-24 21:52","pubTimestamp":1777038730,"startTime":"0","endTime":"0","summary":"维立志博-B在最新公告中披露，已向董事会授予一般性股份购回授权，允许于香港联合交易所购回不超过公司已发行H股总数10%的股份。公司现有已发行股份约1.99亿股，其中H股约1.53亿股，授权规模对应最多可购回约1532.79万股H股。公司将就上述购回授权提交2026年5月15日举行的股东大会进行表决，并将于5月12日至5月15日暂停办理H股过户手续。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B授予董事股份购回授权，规模达已发行H股一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138538734","title":"维立志博PD-L1/4-1BB双抗Opamtistomig（LBL-024）胃癌II期试验启动首例患者给药，开创免疫治疗联合策略新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1138538734","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138538734?lang=zh_cn&edition=full","pubTime":"2026-04-21 21:48","pubTimestamp":1776779309,"startTime":"0","endTime":"0","summary":"维立志博研发的PD-L1/4-1BB双特异性抗体Opamtistomig正式进入II期临床试验阶段，已完成首例胃癌患者给药。这一里程碑事件标志着该创新药物在肿瘤免疫治疗领域迈出关键一步，为探索增强型免疫联合疗法开辟了新路径。作为具有双重作用机制的双抗药物，Opamtistomig通过同时靶向PD-L1和4-1BB信号通路，既能解除肿瘤微环境的免疫抑制，又能激活T细胞免疫应答。该研究将重点评估Opamtistomig在胃癌患者中的安全性和有效性，并为后续临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629089166","title":"维立志博-B(09887)：维利信TM(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)于一线胃或胃食管结合部腺癌II期试验的首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2629089166","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629089166?lang=zh_cn&edition=full","pubTime":"2026-04-21 16:46","pubTimestamp":1776761213,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，评价维利信TM(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)用于治疗一线局部晚期或转移性胃或胃食管结合部腺癌的II期临床研究首例患者已成功入组。本次开展的开放标签、多中心Ⅱ期临床研究由北京大学肿瘤医院沈琳教授牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗用于治疗一线局部晚期或转移性胃或胃食管结合部腺癌患者的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","BK4588","LU1169590202.USD","BK4585","BK4099","TM","BK1161","BK4023","BK4604","HK0000252160.HKD","03160","PD","BK4555","HK0000252152.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629086468","title":"东方证券：维持维立志博-B(09887)“买入”评级 目标价格为103.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629086468","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629086468?lang=zh_cn&edition=full","pubTime":"2026-04-21 15:22","pubTimestamp":1776756123,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：事件公司2025年实现营收1.8亿元，主要系LBL-047成功BD后收到的2500万美元首付及里程碑款项，助力公司营收端实现重大突破。临床进展顺利，LBL-024即将迎来出海关键窗口期截至3月底，LBL-024已在13个实体瘤适应症中推进9项临床研究，累计入组患者超600例。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09887","03958","EWH","600958"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135825634","title":"异动解读 | 核心药物临床进展积极，维立志博-B盘中大涨6.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135825634","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135825634?lang=zh_cn&edition=full","pubTime":"2026-04-14 14:47","pubTimestamp":1776149255,"startTime":"0","endTime":"0","summary":"维立志博-B今日盘中股价大涨6.15%，引起了市场关注。消息面上，此次股价异动与公司核心在研产品LBL-024的临床研究进展密切相关。公司近日公告显示，LBL-024用于一线治疗晚期胆道癌的II期临床研究已完成安全性导入期评估，并顺利进入扩展阶段。初步数据显示，该药物联合化疗方案安全性与耐受性良好，且疗效数据呈现肿瘤缩小趋势，这为药物的后续开发提供了积极信号。此外，有券商报告指出，LBL-024的研发进展是公司当前的关键看点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627904574","title":"港股维立志博-B午后涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627904574","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627904574?lang=zh_cn&edition=full","pubTime":"2026-04-14 14:42","pubTimestamp":1776148942,"startTime":"0","endTime":"0","summary":"4月14日，维立志博-B(09887.HK)午后涨超6%，截至发稿，涨6.15%，报94.95港元，成交额6329.96万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704307322.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704307322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000500386.USD","BK4585","VXUS","HK0000252152.HKD","09887","BK1161","HK0000252160.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626971298","title":"港股维立志博-B涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626971298","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626971298?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:50","pubTimestamp":1775699417,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月9日，维立志博-B(09887.HK)涨超4%，截至发稿涨4.39%，报93.9港元，成交额1337.78万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699195647.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699195647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4585","HK0000252160.HKD","09887","HK0000252152.HKD","HK0000500386.USD","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164229048","title":"异动解读 | 维立志博-B盘中大涨5.06%，维利信®胆道癌Ⅱ期研究进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=1164229048","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164229048?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:45","pubTimestamp":1775699106,"startTime":"0","endTime":"0","summary":"维立志博-B(09887)今日盘中大涨5.06%，引起了市场的广泛关注。消息面上，公司自主研发的PD-L1/4-1BB双特异性抗体维利信®（LBL-024）一线治疗晚期胆道癌的Ⅱ期临床研究已完成安全性导入期初步评估。基于良好的安全性和令人鼓舞的疗效数据，项目顺利进入扩展阶段，并已完成首例入组。数据显示，维利信®联合化疗整体安全性与耐受性良好，未发现新的安全性信号；初步的疗效评估显示的肿瘤缩小趋势令人振奋。这一积极进展增强了市场对公司未来在癌症治疗领域发展的信心，从而推动了股价的上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626605971","title":"港股异动 | 维立志博-B(09887)涨超4% 维利信®一线治疗胆道癌Ⅱ期研究顺利进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2626605971","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626605971?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:41","pubTimestamp":1775698874,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B(09887)涨超4%，截至发稿，涨4.39%，报93.9港元，成交额1337.78万港元。消息面上，4月8日，维立志博宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信®（LBL-024）一线治疗晚期胆道癌的Ⅱ期临床研究已完成安全性导入期初步评估。基于良好的安全性和令人鼓舞的疗效数据，项目顺利进入扩展阶段，并已完成首例入组。数据显示，维利信®联合化疗整体安全性与耐受性良好，未发现新的安全性信号；初步的疗效评估显示的肿瘤缩小趋势令人振奋。基于良好的安全性与令人鼓舞的疗效数据，项目顺利进入扩展阶段并加速推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK4588","HK0000252152.HKD","BK1161","HK0000500386.USD","VXUS","HK0000252160.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625117919","title":"维立志博-B(09887)：维利信TM治疗胆道癌II期研究顺利进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2625117919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625117919?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:34","pubTimestamp":1775637275,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)公布，评价维利信TM(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)用于一线治疗晚期胆道癌的Ⅱ期临床研究已完成安全性导入期初步评估。基于良好的安全性和令人鼓舞的初步疗效数据，该研究已顺利进入扩展阶段，并已完成首例患者入组。该研究由复旦大学附属中山医院周俭院士牵头，正在全国多家医院同步推进。在安全性导入期，共计20例受试者完成初步评估。数据显示维利信TM联合化疗整体安全性与耐受性良好，未发现新的安全性信号。初步的疗效数据亦显示肿瘤缩小趋势令人振奋。基于良好的安全性与令人鼓舞的疗效数据，该研究进入扩展阶段并加速推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03160","09887","HK0000500386.USD","TM","BK1161","BK4585","HK0000252160.HKD","BK4099","HK0000252152.HKD","BK4555","BK4604","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183124933","title":"异动解读 | 维立志博-B(09887)盘中大涨13.24%，因两项临床前研究成果获选AACR年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1183124933","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183124933?lang=zh_cn&edition=full","pubTime":"2026-04-01 12:30","pubTimestamp":1775017825,"startTime":"0","endTime":"0","summary":"维立志博-B(09887)今日盘中股价大幅上涨13.24%，引起了市场的高度关注。消息面上，公司发布公告，宣布其两项临床前管线研究成果将在2026年美国癌症研究协会(AACR)年会上进行展示。这两项研究分别展示了公司在细胞衔接器-药物偶联物及双靶点ADC领域的创新进展，进一步验证了其LeadsBody、X-body及TOPiKinectics三大核心专有技术平台的协同研发战略与潜力。此次研究成果入选国际顶级癌症研究会议，被视为公司研发实力的重要体现，增强了投资者对其未来产品管线价值和长期增长前景的信心，从而推动了股价的显著上扬。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165236663","title":"维立志博-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1165236663","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165236663?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:12","pubTimestamp":1775013178,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司于2026年4月1日披露了截至2026年3月31日的股份变动月报表，报告期为2026年3月1日至2026年3月31日。报告期内，上述各类股份数量和结构均未发生变化。截至3月末，公司全部已发行股份数合计仍为198,891,800股，股本结构保持稳定。公司于月报中声明，所有股份相关事项均已遵守香港联交所《上市规则》及适用法律法规的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624456846","title":"港股异动 | 维立志博-B(09887)早盘涨超10% 两项研究摘要入选2026年AACR年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2624456846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624456846?lang=zh_cn&edition=full","pubTime":"2026-04-01 10:13","pubTimestamp":1775009634,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B早盘涨超10%，截至发稿，涨8.99%，报80.65港元，成交额3218.88万港元。消息面上，维立志博发布公告，两项临床前管线研究成果将在2026年美国癌症研究协会年会上展示。该两项研究分别展示了公司于细胞衔接器-药物偶联物及双靶点ADC的创新研究，进一步验证公司LeadsBody、X-body及TOPiKinectics三大核心专有技术平台的协同研发战略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK4588","BK1161","BK4585","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623304276","title":"维立志博-B(09887)研究摘要入选2026年AACR年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2623304276","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623304276?lang=zh_cn&edition=full","pubTime":"2026-03-31 16:56","pubTimestamp":1774947408,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，两项临床前管线研究成果将在2026年美国癌症研究协会年会上展示。此年会将于2026年4月17日至22日在美国加利福尼亚州圣地亚哥的圣地亚哥会议中心举行。LBL-061是一款新型的EGFR/PD-L1双特异性ADC，通过公司专有的TOPiKineticsTM 连接子载荷平台偶联而成，兼具ADC的肿瘤靶向杀伤与免疫激活，协同增强抗肿瘤效应，适用于头颈癌、非小细胞肺癌、鼻咽癌等实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622763828","title":"维立志博-B(09887)提名吴凤岚为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2622763828","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622763828?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:56","pubTimestamp":1774608989,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，倪佳博士(倪博士)已提呈辞任本公司非执行董事，自2026年3月27日起生效。经考虑董事会提名委员会的推荐建议后，董事会议决提名吴凤岚博士(吴博士)为本公司非执行董事。建议委任吴博士须待股东于本公司年度股东会会议上以普通决议案方式批准后，方告作实。自2026年3月27日起，独立非执行董事及提名委员会成员张宏冰博士已获委任为提名委员会主席。康小强博士不再担任提名委员会主席，但仍留任提名委员会成员。提名委员会的其他组成维持不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","HK0000500386.USD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622841773","title":"维立志博-B(09887)公布2025年业绩 净亏损约2.11亿元 同比减少29.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841773","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622841773?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:04","pubTimestamp":1774602297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 公布2025年业绩，收入约1.77亿元，研发成本约2.89亿元，同比增长55.7%;年内亏损约2.11亿元，同比减少29.8%。研发成本增加主要归因于：CMC开发里程碑开支增加，主要与LBL-024的BLA提交准备有关;临床开发开支增加，主要由于LBL-024和LBL-034的患者入组加速和临床进展;及随着公司将多个管线资产推进至IND准备阶段，临床前开支增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09887","HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618761585","title":"维立志博-B盘中涨超8% 正式进入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2618761585","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618761585?lang=zh_cn&edition=full","pubTime":"2026-03-09 10:35","pubTimestamp":1773023700,"startTime":"0","endTime":"0","summary":"　　维立志博-B盘初涨超8%，截至发稿，股价上涨6.04%，现报57.10港元，成交额1.15亿港元。　　维立志博公布，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。　　此外，3月6日，维立志博宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信联合用药一线治疗局部晚期或转移性食管鳞癌的Ⅱ期临床研究顺利完成首例患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-09/doc-inhqizzu7097010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000252160.HKD","VXUS","HK0000252152.HKD","BK4585","09887","HK0000500386.USD","VT","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617666837","title":"维立志博-B获纳入恒生综合指数成份股及获调入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2617666837","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617666837?lang=zh_cn&edition=full","pubTime":"2026-03-08 10:08","pubTimestamp":1772935680,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　维立志博-B（09887）发布公告，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。\n　　股份获纳入恒生综合指数及港股通标的证券是资本市场对公司表现及价值的高度认可，并允许中国内地合资格投资者透过沪港通及深港通机制直接投资于香港联合交易所有限公司上市的股份。预期纳入将进一步扩大公司的投资者基础，提升股份的交易流动性，并进一步优化股东结构。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-08/doc-inhqfsuq1032680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09887","VXUS","BK4588","VT","HSCI","HK0000500386.USD","HK0000252152.HKD","BK4585","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.0226},{"period":"1month","weight":0.0811},{"period":"3month","weight":0.1967},{"period":"6month","weight":0.4898},{"period":"1year","weight":1.2857},{"period":"ytd","weight":0.5686}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}